| Wang Hao,Huo Bin,Huo Xiaodong,Wang Lili,Hou Dingkun,Zang Li,Wang Jinhuan,Chai Shude,Wang Junjie,Wang Haitao.Efficacy and safety of CT-guided 125Ⅰ seed implantation for treatment of advanced pancreatic cancer: a Meta-analysis[J].Chinese Journal of Radiological Medicine and Protection,2017,37(7):543-549 |
| Efficacy and safety of CT-guided 125Ⅰ seed implantation for treatment of advanced pancreatic cancer: a Meta-analysis |
| Received:January 20, 2017 |
| DOI：10.3760/cma.j.issn.0254-5098.2017.07.014 |
| KeyWords:125Ⅰ seed Brachytherapy Pancreatic cancer Systematic review Meta analysis |
| FundProject:国家自然科学基金（81572543）；国家肿瘤临床医学研究中心个体化医学平台建设项目（13ZCZCSY20300） |
| Author Name | Affiliation | E-mail | | Wang Hao | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Huo Bin | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Huo Xiaodong | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Wang Lili | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Hou Dingkun | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Zang Li | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Wang Jinhuan | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Chai Shude | Department of Thoracic Surgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | Wang Junjie | Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China | | | Wang Haitao | Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China | peterrock2000@126.com |
|
| Hits: 2605 |
| Download times: 1840 |
| Abstract:: |
| Objective To systematically evaluate the efficacy and safety of 125Ⅰ seed implantation for treatment of advanced pancreatic cancer. Methods An electronic literature search was performed about randomized controlled trials(RCTs) of 125Ⅰ implantation for treamtent of advanced pancreatic cancer in CNKI, Wanfang Data, CBM, Cochrane Library, PubMed and Embase (from the date of building the database to November 2016). Two investigators independently screened literature, extracted data and assessed the risk bias of included studies, and the Meta-analysis was performed by using Revman 5.3 software. Results There were 12 RCTs (n=689) included. Meta-analysis showed that the objective respond rate(ORR) (OR=3.24, 95%CI 2.33-4.52, P<0.001), the 6-month survival rate(OR=3.61, 95%CI 1.53-8.52, P=0.003), the 12-month survival rate(OR=4.80, 95%CI 2.40-9.57, P<0.001) and the relief rate of pain were higher than those in the control group. However, there were no significant differences between both groups in the 2-year survival rate and the adverse reaction rate, which were (OR=2.36, 95%CI 0.47-11.74, P=0.29) and (OR=4.94, 95%CI 1.05-23.23, P=0.04), respectively. Conclusions The limited current evidence showed that 125Ⅰ implantation for treatment of advanced pancreatic cancer is effective and safety. 125Ⅰ implantation can improve the ORR, short-time survival rate and pain relief rate. In addition, there was no significant increase in the incidence of related adverse events except for seed malposition. Although the quality and quantity of evidences is limited, it merits further study to provide high quality evidences. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
